0
Det giver næppe den helt store nedtur i.f.t nu $ 25,65.
Provenuet ser ikke ud til, at skulle bruges til køb af Genmabs fabrik !
Men udvidelser af egne.
Provenuet ser ikke ud til, at skulle bruges til køb af Genmabs fabrik !
Men udvidelser af egne.
11/12 2009 16:18 alpehue 023358 Dendreon Announces Pricing of Common Stock Offering
SEATTLE, December 10, 2009 - Dendreon Corporation (Nasdaq: DNDN) announced today that it has priced its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $24.75 per share. Dendreon also granted to the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock to cover overallotments, if any. The offering is expected to close on December 15, 2009, subject to customary closing conditions.
J. P. Morgan Securities Inc. and Deutsche Bank Securities Inc. acted as joint book-running managers of the offering. Citigroup Global Markets Inc., Morgan Stanley & Co. Incorporated, Lazard Capital Markets LLC, Leerink Swann LLC and Needham & Company, LLC acted as co-managers.
Dendreon anticipates net proceeds from the offering of approximately $356.0 million ($409.5 million if the underwriters exercise their overallotment option in full). Dendreon intends to use the net proceeds of the offering to fund expenditures in connection with the investment in its manufacturing facilities, including the accelerated build-out of new facilities in Atlanta, Georgia and Orange County, California (providing for additional capacity from such facilities in mid 2011) and build-out of the remaining capacity at its Morris Plains, New Jersey facility, to fund investment in information technology infrastructure and product support systems, to hire manufacturing, sales and marketing, quality and other personnel in preparation for the licensure by the FDA and commercialization of PROVENGE® (sipuleucel-T), for third-party contract supply costs, and for general corporate purposes, including working capital.
The shares of common stock will be issued pursuant to Dendreon?s effective registration statement on Form S-3 filed with the Securities and Exchange Commission (the ?SEC?). Copies of the prospectus supplement and related base prospectus for this offering, when available, may be obtained by contacting: J.P. Morgan Securities Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling 1-866-803-9204; or Deutsche Bank Securities Inc., Prospectus Department, Harborside Financial Center, 100 Plaza One, Jersey City, New Jersey 07311-3988, or by calling 1-800-503-4611. An electronic copy of the prospectus supplement and related base prospectus for the offering will also be available on the SEC?s website, www.sec.gov.
SEATTLE, December 10, 2009 - Dendreon Corporation (Nasdaq: DNDN) announced today that it has priced its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $24.75 per share. Dendreon also granted to the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock to cover overallotments, if any. The offering is expected to close on December 15, 2009, subject to customary closing conditions.
J. P. Morgan Securities Inc. and Deutsche Bank Securities Inc. acted as joint book-running managers of the offering. Citigroup Global Markets Inc., Morgan Stanley & Co. Incorporated, Lazard Capital Markets LLC, Leerink Swann LLC and Needham & Company, LLC acted as co-managers.
Dendreon anticipates net proceeds from the offering of approximately $356.0 million ($409.5 million if the underwriters exercise their overallotment option in full). Dendreon intends to use the net proceeds of the offering to fund expenditures in connection with the investment in its manufacturing facilities, including the accelerated build-out of new facilities in Atlanta, Georgia and Orange County, California (providing for additional capacity from such facilities in mid 2011) and build-out of the remaining capacity at its Morris Plains, New Jersey facility, to fund investment in information technology infrastructure and product support systems, to hire manufacturing, sales and marketing, quality and other personnel in preparation for the licensure by the FDA and commercialization of PROVENGE® (sipuleucel-T), for third-party contract supply costs, and for general corporate purposes, including working capital.
The shares of common stock will be issued pursuant to Dendreon?s effective registration statement on Form S-3 filed with the Securities and Exchange Commission (the ?SEC?). Copies of the prospectus supplement and related base prospectus for this offering, when available, may be obtained by contacting: J.P. Morgan Securities Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling 1-866-803-9204; or Deutsche Bank Securities Inc., Prospectus Department, Harborside Financial Center, 100 Plaza One, Jersey City, New Jersey 07311-3988, or by calling 1-800-503-4611. An electronic copy of the prospectus supplement and related base prospectus for the offering will also be available on the SEC?s website, www.sec.gov.
11/12 2009 16:34 1970 023360 Der står lidt her om hvad pengene skal bruges til:
http://finance.yahoo.com/news/Dendreon-to-sell-15M-shares-apf-926986353.html?x=0&.v=1
The company wants to use the money to speed construction of new facilities in Atlanta and in Orange County, Calif. It is also building out the remaining capacity at its Morris Plains, N.J. facility.
In addition, proceeds will be used to fund investment in information technology infrastructure and product support systems, and to hire manufacturing, sales and marketing, quality and other personnel in preparation for marketing the prostate cancer treatment Provenge.
http://finance.yahoo.com/news/Dendreon-to-sell-15M-shares-apf-926986353.html?x=0&.v=1
The company wants to use the money to speed construction of new facilities in Atlanta and in Orange County, Calif. It is also building out the remaining capacity at its Morris Plains, N.J. facility.
In addition, proceeds will be used to fund investment in information technology infrastructure and product support systems, and to hire manufacturing, sales and marketing, quality and other personnel in preparation for marketing the prostate cancer treatment Provenge.
